Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations

BACKGROUND: The North-East Japan Study Group (NEJ) 005/Tokyo Cooperative Oncology Group (TCOG) 0902 study has reported that first-line concurrent and sequential alternating combination therapies of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (gefitinib) plus platinum-based d...

Descripción completa

Detalles Bibliográficos
Autores principales: Oizumi, Satoshi, Sugawara, Shunichi, Minato, Koichi, Harada, Toshiyuki, Inoue, Akira, Fujita, Yuka, Maemondo, Makoto, Watanabe, Satoshi, Ito, Kazuhiko, Gemma, Akihiko, Demura, Yoshiki, Fukumoto, Shinichi, Isobe, Hiroshi, Kinoshita, Ichiro, Morita, Satoshi, Kobayashi, Kunihiko, Hagiwara, Koichi, Aiba, Keisuke, Nukiwa, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844373/
https://www.ncbi.nlm.nih.gov/pubmed/29531840
http://dx.doi.org/10.1136/esmoopen-2017-000313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844373/
https://www.ncbi.nlm.nih.gov/pubmed/29531840
http://dx.doi.org/10.1136/esmoopen-2017-000313

Ejemplares similares